Key milestones achieved in commercializing a POC diagnostic platform, with strong clinical results and a fully subscribed SEK 100.3m rights issue. Financials show continued losses during development, but equity and liquidity improved. Market outlook remains robust.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.